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1. Introduction  
DNA repair pathways are targets of numerous anticancer drugs including natural and 
chemical compounds, which direct cancer cells toward apoptosis. However, different types 
of cancer cells consist of various alterations in DNA repair genes that make cancer cells 
become drug-resistant and lead to treatment failure and disease recurrence. On the contrary, 
cancer cells may also possess defects in certain DNA repair pathway that make them are 
susceptible to certain compounds, which inhibit another DNA repair pathway inside the 
cancer cells. As a result, these compounds selectively kill the cancer cells and are less 
harmful to the normal ones. Understanding the effects of anticancer drugs on DNA repair as 
well as the DNA repair activity of cancer cells themselves are important for improvement of 
anticancer treatment. Similarly, this information is helpful for elucidation of the 
carcinogenicity of environmental toxicants. This chapter introduces the crosstalk between 
anticancer drugs, environmental toxicants and DNA repair pathways in head and neck 
cancer. In addition, the application of an easy, fast and measurable in vivo functional assay 
for nucleotide excision repair (NER) and DNA repair via homologous recombination (HR) 
and non-homologous end-joining (NHEJ) pathways is shown to examine the cellular DNA 
repair activity responding to anticancer drugs or environmental toxicants. By which the 
functional roles of DNA repair genes in response to anticancer treatments and genotoxic 
substances could be evolved in head and neck cancer cells.  
2. Roles of DNA repair genes/pathways in cancer development and treatment 
DNA repair genes play a pivotal role in the maintenance of genome integrity. Defects or 
dysregulation of DNA repair genes can result in genomic instability (GIN), which is a common 
feature of cancer cells (Hanahan & Weinberg, 2000). To prevent this, human cells evolve several 
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DNA repair pathways that may interplay each other to repair various types of DNA damages. 
These DNA repair mechanisms include pathways of base excision repair (BER), nucleotide 
excision repair (NER), mismatch repair (MMR), double strand break (DSB) repair through 
homologous recombination (HR) or non-homologous end-joining (NHEJ) and direct repair of 
DNA lesions such as O6-methylguanine by O6-methylguanine-DNA methyltransferase (Sancar 
et al., 2004). Collectively, there are hundreds of DNA repair genes involved in various DNA 
repair pathways that include processes of sense and recognition of DNA lesions, amplification 
and transmission of the damage signal, recruitment of repair proteins to the damage sites, and 
execution of DNA repair (Sancar et al., 2004; Wood et al., 2005). 
2.1 DNA repair genes/signaling in HR and NER pathways 
Upon DNA damaged, histone H2AX, a histone H2A variant, is quickly phosphorylated 
(denoted as -H2AX) in an ataxia telangiectasia mutated (ATM)-dependent manner (Uziel et 
al., 2003). The phosphorylated H2AX serves as an important marker for DNA damages. 
Some genes are also involved in the recognition of DNA damages. They are members of 
MRN complex (Mre11A, RAD50, NBN) for DSB and damage-specific DNA binding protein 1 
and 2 (DDB1 and DDB2), Xeroderma pigmentosum (XP) complementation group C (XPC) 
for UV-induced damages and bulky DNA adducts, which are produced by DNA-damaging 
chemotherapeutic drugs and can be repaired through NER pathway. In addition to H2AX, 
ATM also phosphorylates p53, BRCA1, CHEK1/2 and results in activation of various DNA 
repair pathways as well as induction of cell cycle arrest (Sancar et al., 2004). Generally, the 
genes involved in HR repair include BRCA1, BRCA2, members of RAD51 and Fanconi 
anemia (FA) families, as well as the Bloom syndrome, RecQ helicase-like (BLM) and Werner 
syndrome, RecQ helicase-like (WRN). The genes in NER pathway consists of XP 
complementation group A to G (XPA to XPG), XP complementation group variant (XPV), 
excision repair cross-complementing rodent repair deficiency, complementation group 1 
(ERCC1), replication protein A (RPA), and so on (Sancar et al., 2004; Wood et al., 2005). 
ATM is the key gene for initiating DNA repair signaling. Its downstream targets, both TP53 
and BRCA1 are capable of regulating multiple DNA repair pathways (Deng, 2006; Helton & 
Chen, 2007). BRCA1 encodes a multifunctional protein that maintains genome integrity 
through regulating gene transcription, cell cycle checkpoints, DNA repair (Deng, 2006; 
Yoshida & Miki, 2004), and centrosome duplication (Deng, 2002; Xu et al., 1999). In addition 
to the role in HR, BRCA1 is involved in NER through transactivating the expression of 
DDB2 and XPC (Hartman & Ford, 2002; Takimoto et al., 2002), both of them can also be 
transactivated by p53 (Adimoolam & Ford, 2002; Hwang et al., 1999). Thus, both BRCA1 and 
TP53 can regulate NER pathway. RAD51 is the human homolog of bacteria recA and forms a 
complex with BRCA1 and BRCA2. This interaction is important for proper regulation of 
RAD51 activity inside a cell. Loss of the binding between RAD51 and BRCA complex may 
be a key event leading to GIN and tumorigenesis (Martin et al., 2007). RAD51 contributes 
the key step of HR by mediating homologous pairing and strand exchange between two 
homologous DNA (Richardson, 2005). It has been shown that RAD51 overexpression is 
correlated with GIN and that p53 can transcriptionally inhibits RAD51 expression (Arias-
Lopez et al., 2006; Richardson et al., 2004). 
2.2 DNA repair activity is important for preventing cancer development 
Activation of DNA repair genes has been shown as a critical anticancer barrier in early 
human tumorigenesis. By examining various stages from precancerous lesions to late-stage 
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tumor tissues, DNA repair genes, including ATM, CHEK1/2, and TP53, are found 
predominantly to be highly activated in the precancerous stage of bladder, colon and lung 
epithelia when DNA damages are emerging inside these cells (Bartkova et al., 2005; 
Gorgoulis et al., 2005; Venkitaraman, 2005). Further, DNA repair genes also play a key role 
in the oncogene-induced senescence and prevent cell transformation (Bartkova et al., 2006; 
Braig et al., 2005; Di Micco et al., 2006). In other word, cells that are unable to activate DNA 
repair genes in the early-stage of tumorigenesis are susceptible for malignant 
transformation. These data demonstrated in somatic cancers strongly indicate that defects or 
inactivations of DNA repair genes/pathways are prerequisite for tumor development. 
Besides, several cancer predisposition syndromes are linked to hereditary mutations or 
deletions of DNA repair genes, such as ATM in ataxia telangiectasia, BRCA1 and BRCA2 in 
familial breast and ovarian cancers, XPC and DDB2 in Xeroderma pigmentosum. Hence, 
people with, either inherited or sporadic, inactivated DNA repair genes/pathways are 
prone to cancer development. In this chapter, we will use head and neck cancer as an 
example to illustrate the important role of DNA repair genes/pathways in the development 
and treatment of this malignancy, and demonstrate the application of a functional DNA 
repair assay, host cell reactivation (HCR), in cancer research. 
2.3 DNA repair activity is a critical determinant for efficacy of anticancer treatment 
using chemotherapy or radiotherapy  
The cell-killing mechanisms of radiotherapy and most regimens of chemotherapy are 
dependent on the induction of severe DNA damages, which result in apoptosis of cancer cells. 
Therefore, the DNA repair activity of cancer cells can play an important role in modulating 
patient’s response to these anticancer treatments. For example, the platinum-based anticancer 
chemical, cisplatin is one of the most popular DNA-damaging chemotherapeutic drugs used in 
clinical management. It causes DNA adducts by interstrand crosslinking, which is repaired by 
a combination of NER and HR (Helleday et al., 2008; Miyagawa, 2008). Mutations of NER 
genes, such as XPF or ERCC1, may increase the sensitivity of cells toward cisplatin (Martin et 
al., 2008; Saldivar et al., 2007). In contrast, elevated expression of NER genes usually confers 
resistance to chemotherapy using DNA-damaging regimens. The expression level of BRCA1, 
which plays a primary role in HR and may has a regulatory role in NER (Hartman & Ford, 
2002; Takimoto et al., 2002), is also correlated with chemotherapy efficacy. It has been shown 
that cells with reduced or inactivated BRCA1 are more sensitive to cisplatin but, in contrast, are 
resistant to taxanes, the microtubule-interfering drugs (Husain et al., 1998; Lafarge et al., 2001; 
Mullan et al., 2001). Overexpression of RAD51, a member of BRCA/FA complex involved in 
HR, is also correlated with cisplatin resistance (Bhattacharyya et al., 2000). For ATM, an in vitro 
study showed that partial loss of distal 11q (ATM locus) was associated with decreased IR 
sensitivity in head and neck cancer cell lines (Parikh et al., 2007). Therefore, understanding the 
status of DNA repair genes/activity is thought to be important for the selection of appropriate 
chemotherapeutic regimens and may have a great impact on the clinical treatment as well as 
the patient’s outcome. 
3. Head and neck cancer 
Head and neck squamous cell carcinoma (HNSCC) is the most popular head and neck 
cancer and is the sixth most common cancer in the world. They include malignancies 
originated from the epithelia of larynx, pharynx, oral and nasal cavities.  
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3.1 Some HNSCC risk factors are able to inhibit DNA repair  
Epidemiological evidences have demonstrated that alcohol drinking, betel quid (BQ) 
chewing (especially in South Asia and South-West Pacific area including Taiwan), cigarette 
smoking, and infection of human papillomavirus are risk factors for HNSCC development 
(Haddad & Shin, 2008; IARC, 2004). The carcinogenicity of betel nut has been approved by 
the International Agency for Research on Cancer (IARC), a WHO organization, in 2004 
(IARC, 2004), although the molecular mechanism underlying its carcinogenicity is not fully 
elucidated. In this regard, we have explored the possible effect of arecoline, a major alkaloid 
in betel nut, on DNA repair activity using HCR. We found that arecoline could inhibit the 
repair of UV-induced DNA damages, at least partly, through inactivating p53’s expression 
and transactivation activity (Tsai et al., 2008). Besides, we also showed that arecoline could 
affect mitotic spindles and deregulated mitotic checkpoint, another key guardian of genome 
integrity (Wang et al., 2010). These results provide molecular explanation for BQ-associated 
carcinogenicity that has been shown previously by an increase of mitosis errors and 
micronucleus (MN) in mammalian cells (Lin, 2010). Micronucleus is a typical sign of GIN 
and is derived from either DNA strand breaks (clastogenic effect) or whole chromosome 
lagging during mitosis (aneugenic effect) (Norppa & Falck, 2003). 
Epidemiological studies also show that the probability of HNSCC development is 
synergistically increased by simultaneous exposure of BQ, cigarette, and alcohols (Ko et al., 
1995; Lee et al., 2005). Regarding the carcinogenic role of cigarette on the aspect of DNA 
repair, we also found that benzo(a)pyrene (BaP), an important carcinogen in cigarette 
(IARC, 2010), exhibited negative effects on DNA repair (Lin et al., 2011 manuscript in 
preparation). The mechanistic study regarding the synergistic effect of arecoline and BaP on 
regulating DNA repair, especially via p53- and aryl hydrocarbon receptor-dependent 
pathway, is worthy to be investigated further. 
3.2 Alterations of DNA repair genes/activity in HNSCC and the relationship with 
HNSCC development, treatment, as well as patient’s outcome  
GIN is a hallmark of most human malignancies including HNSCC that elevated 
microsatellite instability, aneuploidy and various genomic alterations have been found by 
genome-wide analyses (Bockmuhl et al., 1996; Brieger et al., 2003; Friedlander, 2001; 
Partridge et al., 1999; Sparano et al., 2006), suggesting that GIN may be involved in the 
development of HNSCC. Some studies also show that DNA repair activity is reduced in the 
peripheral blood cells of HNSCC patients when compared with normal individuals (Cheng 
et al., 1998; Paz-Elizur et al., 2006), implying that altered DNA repair genes and/or activity 
may play a critical role in the development of HNSCC. 
Studies using comparative genomic hybridization (CGH) have shown that gene copy 
numbers at chromosome 11q22-23 (ATM locus) are frequently lost in HNSCC (Bockmuhl et 
al., 1996; Brieger et al., 2003; van den Broek et al., 2007). Lazar et al. also showed loss of 
heterozygosity (LOH) at 11q23 in 25% (13/52) of primary HNSCC (Lazar et al., 1998). In 
addition, we have reported that ATM mRNA is down-regulated in 81.3% (65/80) of 
laryngeal and pharyngeal cancers, and further show that lower ATM expression 
(tumor/normal < 0.3) was an independent risk factor for patient’s survival (Lee et al., 2011). 
This is the first study showing that ATM expression is a valuable prognostic marker for 
HNSCC. One study also shows an absent or reduced ATM protein expression in 31.25% 
(10/32) of oral cancer (He et al., 2008). These results suggest that alteration of ATM, either in 
gene sequence or in expression level may be associated with HNSCC.  
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Previous investigations showed that LOH of chromosome 17q (BRCA1 locus) were found in 
35% to 56% of laryngeal cancer (Kiaris et al., 1995; Rizos et al., 1998). In contrast, studies 
using CGH found an overrepresentation of 17q in 9% to 47% of HNSCC (Bockmuhl et al., 
1996; Brieger et al., 2003), and one array-CGH reported the gain of 17q21 in 33% (7/21) of 
oral cancer (Sparano et al., 2006). These controversial results by genome-wide analyses may 
be due to the physically close localization of ERBB2 (HER-2/neu) oncogene and the results 
need to be clarified by specifically looking at the BRCA1 gene locus. Regarding the 
expression of BRCA1 in HNSCC, one study showed that BRCA1 immunostaining positivity 
was lost in 34% (26/77) of tongue cancers, which might be correlated with early-stage tumor 
progression (Vora et al., 2003). 
The results of genome-wide studies also suggest that genetic alterations at RAD51 (15q15.1) 
and XPC (3p25) loci may be present in HNSCC (Bockmuhl et al., 1996; Brieger et al., 2003; 
Partridge et al., 1999; Sparano et al., 2006; van den Broek et al., 2007). Altered RAD51 protein 
expression has been reported by one pilot study with twelve head and neck cancer patients 
(Connell et al., 2006). The patients with high RAD51 protein levels in their pre-treatment tumor 
biopsies demonstrate poorer cancer-specific survival rates than those with lower RAD51 levels 
(33.3% vs. 88.9% at 2 years; P = 0.025). These results suggest that RAD51 expression may 
influence the outcome of with head and neck cancer patients who receive chemotherapy and 
radiotherapy (Connell et al., 2006). Other reports regarding altered expression of DNA repair 
genes in HNSCC include Ku80 (Chang et al., 2006), NBN and ERCC1 (Hsu et al., 2010; Yang et 
al., 2006). It has been shown that ERCC1 expression is associated with cisplatin resistance 
(Handra-Luca et al., 2007; Hsu et al., 2010) and NBN is correlated with outcome of advanced 
HNSCC patients (Yang et al., 2006). Inactivation of the BRCA/FA pathway via promoter 
methylation has also been described in HNSCC, and may be related to tobacco and alcohol 
exposure and survival of these patients (Marsit et al., 2004).  
3.3 Treatment of HNSCC 
Since HNSCC and its treatment can affect important physiological functions, such as speaking, 
breathing, and swallowing, it is important for choosing the appropriate treatment that not only 
cures but also benefits to the preservation of organs, physiological functions, and quality of 
life. The standard treatment for resectable HNSCC is surgical resection with or without 
postoperative concurrent chemotherapy (cisplatin plus 5-fluorouracil) and radiotherapy 
(CCRT). Around two-thirds of HNSCC are in advanced stage at time of diagnosis (Specenier & 
Vermorken, 2009). The majority of these patients with advanced stage tumors finally relapse 
locoregionally or at distant sites. These patients are usually qualified for palliative treatment 
only. Recent advances in using cetuximab (anti-EGFR) to prolong patient’s survival time in 
locally advanced HNSCC is a big, but still not a fully satisfied progress (Vermorken et al., 
2008). The use of docetaxel (a spindle poison and mitotic catastrophe inducer) can enhance the 
efficacy of chemotherapy using cisplatin/fluorouracil and improve slightly the overall 
survival rates of HNSCC patients (Hitt et al., 2005; Posner et al., 2007; Vermorken et al., 2007). 
These results suggest that a combination regimen exploiting different cell-killing mechanisms 
may be superior to monotherapy. However, an ideal combination regimen with lower adverse 
and side effects for efficient treatment of HNSCC is still under looking for. 
3.4 Understanding the status of DNA repair genes in HNSCC is important for design of 
an effective therapeutic strategy for this malignancy 
Since DNA repair genes/activity play a key role in cancer development and treatment, 
understanding their expression and genomic/functional alterations may facilitate the 
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identification of new predictive or prognostic markers and new therapeutic targets for 
treatment of HNSCC. For example, recent studies using the strategy of synthetic lethal 
interaction (SLI) to improve efficacy of cancer treatment have become an attractive strategy 
(Helleday et al., 2008). Cancer cells that can survive from innumerable genetic alterations are 
largely dependent on the activities of multiple DNA repair pathways. However, cancer cells 
may also be defective in certain DNA repair pathway that is inherent or arises during 
tumorigenesis. Therefore, inhibition of one DNA repair pathway may increase selectively 
killing of cancer cells that already have another defective DNA repair pathway. For examples, 
some clinical trials have shown the efficient killing of BRCA1- or BRCA2-defective cancer cells 
(with defective HR repair) by using PARP1 inhibitors, which block BER pathway (Annunziata 
& O'Shaughnessy, 2010; Bryant et al., 2005; Farmer et al., 2005; Underhill et al., 2010). Notably, 
such kind of treatment is less toxic than conventional radiotherapy and chemotherapy. This 
may benefit to organ preservation of HNSCC patients if one can identify SLI targets (DNA 
repair genes are good candidates) and develop corresponding regimens for treatment. For this 
reason, some clinical trials are ongoing to examine the efficacy of anticancer treatments by 
modulating DNA repair activities that are involved in different DNA repair pathways 
(Bolderson et al., 2009; Helleday, 2010; Helleday et al., 2008). 
4. Host cell reactivation (HCR) assay 
As mentioned above, DNA repair activity plays a critical role in maintaining genome 
integrity. Regardless the alterations of DNA repair genes at the levels of gene expression or 
DNA sequence, measurement of DNA repair activity can reflect the overall biological effects 
that are as consequences of these molecular changes and/or anticancer drug responses. 
Here we describe an easy and fast functional assay (HCR) to evaluate cellular DNA repair 
activity in vivo. This method uses a plasmid that can produce luciferase in mammalian cells 
as a reporter. We choose luciferase as a reporter since its characteristics of high sensitivity 
and wide dynamic linear range for quantification. Of course, other commonly used 
reporters, such as chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase 
(SEAP) or green fluorescent protein (GFP) can also be used.  
The reporter is damaged in vitro first and is transfected into host cells. If the damaged 
reporter plasmid can be repaired in the host cells, the luciferase will be re-expressed. 
Otherwise, the luciferase activity will be much lower than that transfected with undamaged 
control plasmid. By this way, one can determine the DNA repair capacity by simply 
measuring luciferase activity. The reporter plasmid can be damaged using various methods 
such as UV, chemicals or restriction enzymes and serve as substrates for different DNA 
repair pathways. In this chapter, we will demonstrate the use of HCR in evaluating DNA 
repair capacities via NER, HR and NHEJ pathways. 
4.1 HCR for NER  
NER is responsible for the repair of bulky DNA lesions induced by UV and a lot of 
anticancer drugs. Here we use UV as a method to damage a luciferase reporter plasmid. 
Other chemicals (such as cisplatin) that cause bulky DNA adducts can also be used.  
4.1.1 Materials  
1. The reporter plasmid: pCMV-Luc (Liu et al., 2004). The firefly luciferase is driven by the 
cytomegalovirus (CMV) immediate early (IE) gene promoter. 
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2. The internal control plasmid used for calibrating transfection efficiency: pRL-CMV 
(Promega, Cat. No. E2261). The Renilla luciferase is driven by the CMV IE promoter. 
3. Transfection reagents: LipofectamineTM 2000 (Invitrogen, Cat. No. 11668) and Opti-
MEM® I reduced serum medium (Invitrogen, Cat. No. 31985). 
4. The Dual-GloTM Luciferase assay system (Promega, Cat. No. E2940) for analyzing firefly 
and Renilla luciferase activities.  
4.1.2 Substrate preparation for NER 
1. Amplify the pCMV-Luc and pRL-CMV plasmids in E. coli (Fig. 1A). 
2. Harvest bacteria by centrifugation at 13,000 rpm for 15 minutes, discard the supernatant 
completely and purify plasmids using the Plasmid Midi Kit (Geneaid, Cat. No. PI025). 
3. Determine plasmid DNA concentration and purity by measuring the absorbance at 260 
nm and 280 nm with a UV spectrophotometer. 
4. Prepare UV-damaged luciferase reporter plasmid (pCMV-Luc) with a UV-crosslinker 
(CL-1000, UVP). The plasmids are placed within inner side of an opened eppendorf lid 
(Fig. 1B) or 35 mm petri dish without lid. The UV dose for irradiation is dependent on 
cell types because of differential intrinsic DNA repair capacities of various cells. We use 
1000 J/m2 for 293 (human embryonic kidney), Beas-2B (human bronchial epithelium), 
H1299 (human lung cancer), HEp-2 (human laryngeal cancer), SAS, Ca9-22, (human 
oral cancer) and 500 J/m2 for KB (human oral cancer) cells. It is important to keep above 
parameters (the same plasmid amount in a fixed volume for UV irradiation) 
consistently in each experiment, or prepare an enough quantity of UV-dameged 
plasmids that can be stored in aliquots at -80°C once for all experiments. 
4.1.3 Transfection  
1. The HEp-2 cells (6104) are seeded in 24-well plates 24 h prior to transfection (the 
appropriate cell numbers for seeding are dependent on cell types). 
2. Prepare DNA-LipofectamineTM 2000 (Invitrogen) complexes for each sample as follows: 
a. Add 0.5 g of UV-damaged or undamaged (serve as a control) pCMV-Luc together 
with 0.05 g of internal control plasmid (pRL-CMV, Promega) in 50 μl of Opti-
MEM (Invitrogen) medium, mix gently. 
b. Mix 1 l LipofectamineTM 2000 gently in 50 μl of Opti-MEM medium and incubate 
for 5 minutes at room temperature.  
c. Combine the diluted DNA with the diluted LipofectamineTM 2000 (total volume is 
100 μl). Mix gently and incubate for 20 min at room temperature to allow the 
formation of DNA-LipofectamineTM 2000 complexes.  
3. Add the 100 μl of DNA-LipofectamineTM 2000 complexes to each well and incubate at 
37°C in a CO2 incubator for 6 h. Then the cells can be treated with toxicants (such as 
arecoline) or anticancer drugs for another 24 h. Note: cells can be treated with toxicants 
or anticancer drugs prior to transfection that is dependent on experimental design. 
4.1.4 Dual-luciferase assay  
1. After 24 h post-transfection, cells are harvested in 100 l (adjustable) lysis buffer (0.1 M 
HEPES, pH 7.8, 1% Triton X-100, 1 mM CaCl2 and 1 mM MgCl2) with cell scrapers.  
2. The cell lysates are transferred to eppendorf tubes and centrifuged at 13,000 rpm at 
20°C for one minute.  
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3. The supernatants (50 l, adjustable) are transferred into a 96-well plate and 20 l of 
Dual-Glo™ Luciferase Reagent (Promega) are added to each well.  
4. Ten minutes later, the firefly luminescence is measured by a microplate luminometer 
(Centro LB 960, Berthold, Bad Wildbad, Germany). 
5. Add 20 l of Dual-Glo™ Stop & Glo® Reagent (Promega) to each well and wait for 10 
minutes, then the Renilla luminescence is read.  
6. The transfection efficiency-adjusted firefly luciferase activity is obtained by dividing the 
Renilla luciferase activity.   
4.1.5 Representation of NER activity by HCR assay 
Since the pCMV-Luc is damaged by UV, the DNA repair activity (responsible to UV) can be 
represented as the Renilla–calibrated firefly luciferase activity derived from UV-damaged 
pCMV-Luc verse to those from undamaged pCMV-Luc. By this way, one can compare the 
effects of various environmental toxicants on cellular DNA repair capacity. For example, an 
inhibitory effect of arecoline on the repair of UV-damaged pCMV-Luc can be found by 
using HCR assay (Fig. 1C). 
 
 
      
Fig. 1. Schematic illustration of host cell reactivation (HCR) assay for examination of 
nucleotide excision repair. 
(A) The reporter plasmid pCMV-Luc is prepared in E. coli. 
(B) The pCMV-Luc is damaged by 1000 J/m2 of UV light. 
(C) Comparison of the effects of arecoline (ARE, 0.3 mM) and its vehicle (distilled water) on 
the repair of UV-damaged pCMV-Luc in HEp-2 cells. 
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4.2 HCR for HR repair 
HR is a reliable mechanism to accurately repair DNA double strand breaks. Here we use 
PCR to generate two overlapping DNA fragments that contain i) CMV IE promoter and 5’-
part of Renilla luciferase gene, ii) 3’-part of Renilla luciferase gene and poly-A tail sequence 
from pRL-CMV (Fig. 2A) and serve as substrates for HR (Fig. 2B). The two overlapping 
DNA fragments can also be produced by restriction enzyme digestion and gel elution. 
4.2.1 Materials  
1. Plasmids: pRL-CMV (Promega, Cat. No. E2261) and pCMV-Luc (Liu et al., 2004). 
2. PCR primers: RL_1: 5’-AGA TCT TCA ATA TTG GCC ATT AGC; RL_2: 5’-TTC TTA 
TTT ATG GCG ACA TGT TGT; RL_3: 5’-ACG AGG CCA TGA TAA TGT TGG ACG; 
RL_4: 5’-CTT ATC GAT TTT ACC ACA TTT GTA. 
3. DNA Polymerase: Ex Taq™ Polymerase (Takara, Cat No. RR001A). 
4. Gel-MTM Gel Extraction System (Viogene, Cat No. EG1002). 
4.2.2 Substrate preparation for HR repair 
1. Set up PCR reaction as below: 
 
Reaction mixtures HR_13 (l) HR_24 (l) 
10PCR buffer 5 5 
dNTP (2.5 mM) 4 4 
RL_1 primer (10 M) 2 - 
RL_3 primer (10 M) 2 - 
RL_2 primer (10 M) - 2 
RL_4 primer (10 M) - 2 
ExTaq polymerase (5u/l) 0.25 0.25 
Template (40 ng/l) 1 1 
DNA/RNAase free- H2O 35.75 35.75 
Total volume (l) 50 50 
 
2. Incubate the PCR reaction mixtures at 94°C for 2 min, then run for 30 cycles of 
amplification (94°C, 45 sec; 55°C, 1 min; 72°C, 1 min) and additional extension step at 
72°C for 5 min.  
3. Purify the PCR products of HR13 fragments (1730 bp, containing CMV IE promoter and 
5’-part of Renilla luciferase gene) and HR24 fregments (1023 bp, containing 3’-part of 
Renilla luciferase gene and poly-A tail) from 0.8% agarose gels (Fig. 2C) using the Gel-
MTM Gel Extraction System kit (Viogene). 
4. Determine DNA concentration and purity by measuring the absorbance at 260 nm and 
280 nm with a UV spectrophotometer. Dilute the HR13-PCR products to 17 ng/l and 
HR24-PCR products to 10 ng/l with distilled H2O to make the molar ratio of 
HR13:HR24 = 1:1, by which the same volume of the two DNA fragments can be used 
for transfection. Store the purified DNA in aliquots at -20°C. 
Alternative: the two DNA fragments used for HR can also be generated by using a 
combination of restriction endonucleases BglII/NheI and PstI/BamHI for pRL-CMV 
(Progema). The use of former restriction enzymes will produce a DNA fragment containing 
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CMV IE promoter and 5’-part of Renilla luciferase gene, the later ones result in 3’-part of 
Renilla luciferase gene and the poly-A signal. These two DNA fragments contain a 222-bp 
overlapping region for recombination (Fig. 2D). 
 
   
   
Fig. 2. Schematic representation of substrate preparation for HCR assay of homologous 
recombination (HR) repair. 
(A) Location of PCR primers on the pRL-CMV reporter plasmid. 
(B) Agarose gel electrophoresis of the PCR products, which serve as HR substrates.  
(C) Homologous recombination of the two PCR fragments results in expression of luciferase. 
(D) An alternative way to produce DNA fragments for HR by using restriction enzymes.  
4.2.3 Transfection, dual-luciferase assay and representation of HR repair activity 
1. The HEp-2 cells (6104) are seeded in 24-well plates 24 h prior to transfection (the 
appropriate cell numbers for seeding are dependent on cell types). 
2. Prepare DNA-LipofectamineTM 2000 (Invitrogen) complexes for each sample as follows: 
a. Add 4 l each of HR13 and HR24 DNA fragments together with 0.25 g of internal 
control plasmid (pCMV-Luc) in 50 μl of Opti-MEM (Invitrogen) medium, mix gently. 
b. Mix 1 l LipofectamineTM 2000 gently in 50 μl of Opti-MEM medium and incubate 
for 5 minutes at room temperature.  
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c. Combine the diluted DNA with the diluted LipofectamineTM 2000 (total volume is 
100 μl). Mix gently and incubate for 20 min at room temperature to allow the 
formation of DNA-LipofectamineTM 2000 complexes.  
3. Add the 100 μl of DNA-LipofectamineTM 2000 complexes to each well and incubate at 
37°C in a CO2 incubator for 6 h. Then the cells can be treated with toxicants (such as 
areca nut extracts, ANE) or anticancer drugs for another 24 h. Note: cells can be treated 
with toxicants or anticancer drugs prior to transfection that is dependent on 
experimental design. 
4. Perform dual-luciferase assay as section 4.1.4. 
5. Determine the HR activity by comparing the firefly luciferase-calibrated Renilla 
luciferase activities between the environmental toxicants- or anticancer drugs-treated 
cells and vehicle-treated control cells. For examples, the treatment of anticancer drug 
camptothecin (CPT, a topoisomerase I inhibitor) can potentiate HR repair activity but 
the areca nut extracts (ANE) repress HR repair in HEp-2 cells (Fig. 3).  
 
 
Fig. 3. The use of HCR assays in evaluating the effects of camptothecin and areca nut 
extracts on homologous recombination repair. 
(A) Using the method illustrated in Fig. 2D, the Renilla luciferase activity (reflecting the HCR 
activity in Y-axis) can only be detected in the presence of both two DNA fragments (N+P, 
lane 3) but not in cells transfected with only one fragment (NheI or PstI, lanes 1 and 2). 
Treatment of camptothecin (CPT) stimulates HR repair efficiency in the cells (lane 4). 
(B) Dose-dependent repression of HR repair activity by areca nut extracts (ANE). 
4.3 HCR for NHEJ repair 
NHEJ is another DNA repair mechanism responsible to DSB. Unlike HR repair using sister-
chromatids as templates, NHEJ directly joins the broken DNA ends by trimming a few 
nucleotides on the ends. Therefore, it is thought as an error-prone repair system. In this 
regard, we prepare two kinds of reporter DNA substrates that are suitable for analyzing the 
precise and overall NHEJ repair activities, respectively.  
For overall NHEJ repair, pRL-CMV is linearized with HindIII that cuts the flanking 
sequence between CMV promoter and the Renilla luciferase coding sequence. The luciferase 
will express after re-ligation regardless the loss of some nucleotides. For examining precise 
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NHEJ, Afl III that digests the coding region of Renilla luciferase gene is used and the 
luciferase can only be expressed after exact repair (Fig. 4A). The linearized reporter DNA 
fragments are purified, transfected into host cells and examined for luciferase activity as 
described above. Below is an example of evaluating the effect of areca nut extracts on precise 
and overall NHEJ repair (Fig. 4B). 
 
 
 
Fig. 4. HCR assay for non-homologous end-joining (NHEJ) repair.  
(A) The Afl III-digested pRL-CMV is used as a substrate for analyzing precise NHEJ repair 
activity because of the need of exact joining of the Renilla luciferase coding sequence. For 
overall NHEJ, Hind III that cuts the flanking sequence between CMV promoter and the 
Renilla luciferase gene is used. The expression of luciferase is not affected by loss of a few 
nucleotides in this region during the end-joining process. 
(B) The effect of areca nut extracts (ANE, 800 mg/ml for 24 h) on precise (left panel) and 
overall (right panel) NHEJ repair.  
5. Conclusion 
DNA repair genes play a pivotal role in the maintenance of genome integrity. Alterations of 
various DNA repair genes, either in gene sequence/structure or in gene expression, are 
frequently found in most of human malignancies. Since DNA repair activity is able to 
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modulate cellular response to DNA-damaging anticancer drugs, alterations of DNA repair 
genes may be involved in the development of resistance to chemotherapy and radiotherapy. 
In addition, DNA repair activity plays an important role in preventing the mutagenicity and 
cytotoxicity induced by numerous environmental carcinogens and toxicants. Cells with 
reduced DNA repair activity may thus be prone to pathological transformation. Therefore, 
examining the DNA repair activity of a cell can help us to understand the probability of 
cellular tumorigenicity associated with exposure of environmental carcinogens and is able 
to assess the responses of various regimens of anticancer treatment. HCR assay is an easy 
and fast functional assay that can be applied to investigate several DNA repair pathways 
and is one of the most useful methods for evaluating cellular DNA repair activity in vivo.  
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